Compare Hinge Health Inc. Class A Common Stock (HNGE) vs Nike Inc (NKE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hinge Health Inc. Class A Common Stock vs Nike Inc — how do they compare? Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B), while Nike Inc trades at $35.04 (market cap $52.48B). The key difference: Nike Inc is far larger — about 6.2× Hinge Health Inc. Class A Common Stock's market cap, and Nike Inc pays a 4.64% dividend while Hinge Health Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and Nike Inc for 155 Days on average.
| HNGE | NKE | |
|---|---|---|
Market Cap | $8.48B | $52.48B |
Volume | 879,799 | 30,189,626 |
Sector | Health | Consumer Cyclical |
52-Week High | $105.14 | $69.68 |
52-Week Low | $31.17 | $33.87 |
Typical Hold Time | 0 Days | 155 Days |
Enterprise Value | $8.10B | $55.18B |
Dividend Yield | — | 4.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Nike (NKE) trades at $35.35, up 1.84% with a bearish technical signal despite recent earnings beats. The stock faces headwinds from declining revenue ($46.31B in 2025 vs. $51.4B in 2024) and compressed margins (net margin 6.74%), though valuation appears reasonable with P/E of 16.9. Analyst consensus remains mixed with 47% buy ratings but a $36.80 price target suggesting limited upside. Recent news highlights inventory challenges and China market pressures.
Nike's turnaround strategy focuses on inventory discipline and digital DTC growth, but execution risks persist amid weak consumer demand. The stock offers moderate value at current levels with dividend support, though revenue stabilization is critical for sustained recovery. Near-term catalysts include Q4 2026 earnings on June 30, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →About Nike Inc
NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.
Read more on NKE →
